About the Company
Repligen Corporation is an American company devoted to the development and production of materials used in the manufacture of biological drugs.2014 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. In February 2014, Repligen had employed 116 people, about 50% of these based in Sweden.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on REPLIGEN CORP
Repligen Corporation to Present at Upcoming September Conferences
The Bank of America Global Healthcare Conference, being held September 23 – 25 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at ...
Do Options Traders Know Something About Repligen Stock We Don't?
Investors in Repligen Corporation RGEN need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 19, 2025 $135 Call had some of the highest implied ...
Earnings Beat: Repligen Corporation Just Beat Analyst ... - Nasdaq
Repligen Corporation (NASDAQ:RGEN) defied analyst predictions to release its third-quarter results, which were ahead of market expectations. The company beat both earnings and revenue forecasts ...
Why Repligen Corporation Shares Are Falling - Fox Business
Source: Repligen What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly ...
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
Repligen Corporation RGEN reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 ...
Do You Believe in the Growth Prospects of Repligen Corp. (RGEN)?
Repligen Corporation (NASDAQ:RGEN) develops and distributes bioprocessing technologies and systems. The one-month return of Repligen Corporation (NASDAQ:RGEN) was 31.34%, and its shares gained 3. ...
Repligen Corporation: Still Navigating Through The Covid Cliff
Repligen Corporation exceeds Q2 revenue expectations with consumables & biopharma growth. Click to see RGEN's diversification ...
Repligen Stock: Still Quite Overvalued - Seeking Alpha
Repligen Corporation stock is overvalued by several valuation metrics, including P/E and P/S. Read more to see my analysis on RGEN stock.
Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before the bell. Here’s what to look for.
Repligen Corporation Jumped 14.6% in February -- Here's Why
What: Shareholders of Repligen Corporation, a life sciences supply company, were treated to a profitable February as the company's stock gained 14.6% during the month, according to data from S&P ...
Should You Investigate Repligen Corporation (NASDAQ:RGEN) At US$227?
Today we're going to take a look at the well-established Repligen Corporation (NASDAQ:RGEN). The company's stock saw a significant share price rise of over 20% in the past couple of months on the ...
Why Repligen Is Up More Than 10% Today - The Motley Fool
Income guidance was similarly adjusted, with Repligen Corporation now looking for a 2022 operating bottom line of between $3.07 and $3.15 per share. The analyst community had been modeling an ...
Similar Companies
Loading the latest forecasts...